Go Deep
Dr. Lal PathLabs Limited
Dr. Lal PathLabs Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 17,022 | 61.4 | 13.28 | 0.08 | 1,995.00 |
| Oct 2026 | 16,763 | 59.7 | 12.89 | 0.08 | 1,933.60 |
Dr. Lal PathLabs Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 7,977,000,000.0 | 7,027,000,000.0 | 6,598,000,000.0 | — |
| Net Profit | 1,695,000,000.0 | 1,313,000,000.0 | 905,000,000.0 | — |
| EPS | 10.2 | 7.9 | 5.4 | 9.0 |
Dr. Lal PathLabs Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 27,627,650,000.0 | 24,612,220,000.0 | 22,265,020,000.0 | 20,166,430,000.0 |
| Net Profit | 5,047,790,000.0 | 4,871,380,000.0 | 3,577,350,000.0 | 2,388,480,000.0 |
| EPS | 30.2 | 29.2 | 21.5 | 14.4 |
Dr. Lal PathLabs Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 31,459,960,000.0 | 27,167,870,000.0 | 24,559,630,000.0 | 23,855,620,000.0 | — |
| Total Liabilities | 6,047,130,000.0 | 5,103,090,000.0 | 5,705,990,000.0 | 6,860,170,000.0 | — |
| Total Equity | 25,081,390,000.0 | 21,727,150,000.0 | 18,492,830,000.0 | 16,662,980,000.0 | — |
Owes vs Owns
Dr. Lal PathLabs Limited owed ₹0.19 for every ₹1 it owned in Mar 2026, down from ₹0.29 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.19× | 0.19× | 0.23× | 0.29× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Dr. Lal PathLabs Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 42.3%Receivables 3.5%Inventory 1.4%Fixed assets (tangible) 15.6%Intangible assets 23.5%Long-term investments 6.2%Other assets 7.5%
How it's funded — Mar 2026
Short-term debt 1.7%Long-term debt 4.6%Payables 5.7%Other liabilities 7.2%Shareholders' equity 80.8%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 1,330.7 | 1,164.1 | 942.6 | 814.3 |
| Receivables | 110.7 | 88.1 | 77.4 | 70.8 |
| Inventory | 43.9 | 36.1 | 37.3 | 33.8 |
| Fixed assets (tangible) | 489.8 | 342.7 | 348.4 | 404.9 |
| Intangible assets | 740.8 | 799.2 | 852.5 | 906.0 |
| Long-term investments | 195.7 | 67.7 | 19.2 | 26.4 |
| Other assets | 234.4 | 219.0 | 178.5 | 129.2 |
| Liabilities & equity | ||||
| Short-term debt | 53.6 | 0.0 | 83.3 | 153.3 |
| Long-term debt | 145.4 | 102.6 | 0.0 | 83.3 |
| Payables | 180.6 | 167.1 | 186.6 | 156.1 |
| Other liabilities | 225.1 | 240.6 | 300.7 | 293.2 |
| Shareholders' equity | 2,541.3 | 2,206.5 | 1,885.4 | 1,699.5 |
| Net tangible assets | 1,767.4 | 1,373.5 | 996.8 | 760.3 |
Dr. Lal PathLabs Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 6,356,080,000.0 | 5,688,850,000.0 | 5,353,340,000.0 | 4,560,270,000.0 | — |
| Investing Activities | -4,218,640,000.0 | -3,031,630,000.0 | -242,690,000.0 | -2,873,080,000.0 | — |
| Financing Activities | -2,635,720,000.0 | -3,340,290,000.0 | -4,138,630,000.0 | -2,831,830,000.0 | — |